Finally, CXCR4 siRNA was efficiently delivered into the cytoplasm of MDA-MB-231 breast cancer cells and inhibited the protein expression of CXCR4 with an efficacy comparable to that of a commercial transfection reagent. Here, CXCR4 is linked to breast carcinoma.